IGH-MAFB Fusion is an inclusion criterion in 19 clinical trials for multiple myeloma, of which 12 are open and 7 are closed. Of the trials that contain IGH-MAFB Fusion and multiple myeloma as inclusion criteria, 5 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), and 11 are phase 2 (7 open) [5].

IGH-MAFB Fusion is an inclusion criterion in 10 clinical trials for plasma cell leukemia, of which 6 are open and 4 are closed. Of the trials that contain IGH-MAFB Fusion and plasma cell leukemia as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 7 are phase 2 (5 open) [5].

IGH-MAFB Fusion is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IGH-MAFB Fusion and non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open) [5].

IGH-MAFB Fusion is an inclusion criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain IGH-MAFB Fusion and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

IGH-MAFB Fusion is an inclusion criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain IGH-MAFB Fusion and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

IGH-MAFB Fusion is an inclusion criterion in 2 clinical trials for chronic lymphocytic leukemia, of which 2 are open and 0 are closed. Of the trials that contain IGH-MAFB Fusion and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

IGH-MAFB Fusion is an inclusion criterion in 2 clinical trials for chronic myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain IGH-MAFB Fusion and chronic myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

IGH-MAFB Fusion is an inclusion criterion in 2 clinical trials for hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IGH-MAFB Fusion and hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open) [5].

IGH-MAFB Fusion is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain IGH-MAFB Fusion and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

IGH-MAFB Fusion is an inclusion criterion in 1 clinical trial for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH-MAFB Fusion and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IGH-MAFB Fusion is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH-MAFB Fusion and lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

IGH-MAFB Fusion is an inclusion criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains IGH-MAFB Fusion and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [5].

IGH-MAFB Fusion is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains IGH-MAFB Fusion and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

IGH-MAFB Fusion is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH-MAFB Fusion and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IGH-MAFB Fusion is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH-MAFB Fusion and double-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IGH-MAFB Fusion is an inclusion criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH-MAFB Fusion and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IGH-MAFB Fusion is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH-MAFB Fusion and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IGH-MAFB Fusion is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH-MAFB Fusion and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IGH-MAFB Fusion is an inclusion criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains IGH-MAFB Fusion and myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [5].

IGH-MAFB Fusion is an inclusion criterion in 1 clinical trial for plasmacytoma, of which 1 is open and 0 are closed. Of the trial that contains IGH-MAFB Fusion and plasmacytoma as inclusion criteria, 1 is phase 2 (1 open) [5].

IGH-MAFB Fusion is an inclusion criterion in 1 clinical trial for prolymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains IGH-MAFB Fusion and prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

IGH-MAFB Fusion is an inclusion criterion in 1 clinical trial for therapy-related chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains IGH-MAFB Fusion and therapy-related chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

IGH-MAFB Fusion is an inclusion criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains IGH-MAFB Fusion and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [5].

IGH-MAFB Fusion is an inclusion criterion in 1 clinical trial for triple-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH-MAFB Fusion and triple-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].